Lars Ekman - 14 May 2025 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Role
Director
Signature
/s/ Michael J. Malecek, as Attorney-in-Fact for Lars G. Ekman
Issuer symbol
PRTA
Transactions as of
14 May 2025
Net transactions value
$0
Form type
4
Filing time
16 May 2025, 16:51:38 UTC
Previous filing
17 May 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ekman Lars Director C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE /s/ Michael J. Malecek, as Attorney-in-Fact for Lars G. Ekman 16 May 2025 0001376117

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRTA Stock Option (Right to Buy) Award $0 +20,183 $0.000000 20,183 14 May 2025 Ordinary Shares 20,183 $6.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2026 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.